Rosacea is a chronic and progressive skin disease characterized by breakouts, redness, and pus-filled bumps on the face. Topical therapies provide a non-invasive option to treat the symptoms of rosacea and suppress inflammation and acne-like lesions without extensive downtime. These therapeutic creams and gels aim to relieve redness and reduce papules and pustules on the skin when applied regularly. The global rosacea treatment market is estimated to be valued at US$ 1.91 Bn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Increased adoption of topical therapies for treating mild-to-moderate rosacea has been a major trend fueling the growth of the rosacea treatment market. Topical brimonidine, azelaic acid, ivermectin, and bactroban are among the mostly prescribed therapies to manage visible signs of rosacea. Their localized application prevents systemic absorption and minimizes the risk of treatment side effects. This has made topical drugs an attractive first-line treatment option compared to oral medications or laser therapies. Wider availability of newer topical formulations promising enhanced efficacy and gentler application is further supporting increased reliance on topical therapies for long-term management of rosacea.
Segment Analysis

The global rosacea treatment market is dominated by topical drugs sub-segment. Topical drugs are generally prescribed as first-line treatment and include gels, creams, lotions, and ointments containing ingredients like metronidazole, azelaic acid, brimonidine, ivermectin, and sodium sulfacetamide that can help reduce pimples, bumps and swelling. These drugs are preferred options for rosacea as they cause fewer side effects than other options and can effectively treat mild to moderate rosacea symptoms.

Key Takeaways

The global Rosacea Treatment Market Share is expected to witness high growth over the forecast period of 2023 to 2030.

Regional analysis: The North America rosacea treatment market holds the largest market share currently and is expected to maintain its dominance over the forecast period. This can be attributed to growing research into new treatments, rising prevalence of rosacea, and increasing awareness about the condition.

Key players: Key players operating in the rosacea treatment market are Galderma SA, Allergan plc (AbbVie Inc.), Bayer AG, Pfizer Inc., Leo Pharma A/S, Sol-Gel Technologies Ltd., Foamix Pharmaceuticals Ltd., Mayne Pharma, Group Limited, AnaptysBio, Inc., Mylan N.V. Galderma leads the market with its prescription topical drugs branded as Soolantra and Oracea that are prescribed as first-line treatment options.

Get more insights on this topic:

Comments (0)
No login
Login or register to post your comment